🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
✕
Login
Home
News
Messages
Startup Showcase
Trackers
Premium
Premium Content
Jobs
Notifications
Settings
Try our Valuation Calculator →
Log In
News on Medial
Zydus Lifesciences to acquire 50% stake in Sterling Biotech from Perfect Day
YourStory
·
11m ago
Medial
Zydus Lifesciences has signed a contract with Perfect Day Inc to acquire a 50% stake in Sterling Biotech. Perfect Day Inc will sell its shareholding in Sterling Biotech as part of the agreement. After the deal, Sterling Biotech will become a 50:50 joint venture with equal representation on the board. The joint venture plans to establish a manufacturing facility to produce fermented animal-free protein for global markets. This acquisition allows Zydus to enter the specialized biotech products market and cater to consumers who prefer animal-free protein or have lactose intolerance.
View Source
Related News
Temasek-backed firm, Zydus may recast API, gelatine business of Sterling Biotech
VCCircle
·
11m ago
Medial
Zydus Lifesciences Ltd and Perfect Day Inc, the owners of Sterling Biotech, intend to restructure certain aspects of their joint venture. This includes plans to revamp the active pharmaceutical ingredient (API) and gelatine businesses. Zydus Lifesciences previously entered into a partnership agreement with Temasek-backed food technology company. No further details were provided.
View Source
Zydus Life acquires Sterling Biotech’s API formulation business
VCCircle
·
10m ago
Medial
Zydus Lifesciences, a listed pharma company, has acquired the active pharmaceutical ingredients (API) business of Sterling Biotech for Rs 84 crore ($10 million). The acquisition is set to be completed by the end of 2024. Zydus is looking to expand in the fermentation-based API space, which offers high entry barriers and attractive margins. This move aligns with their strategic and commercial goals. The sale of Sterling Biotech's API business is part of their broader strategy to focus on animal-free protein products.
View Source
Grapevine: Zydus joins Torrent in race for JB Chemicals; The New Shop eyes 24Seven
VCCircle
·
1y ago
Medial
In the race to acquire JB Chemicals and Pharmaceuticals, Torrent Pharmaceuticals and Zydus Lifesciences are competing with private equity firm EQT. They have been shortlisted by KKR, the current owner of JB Chemicals. This comes after earlier reports of Torrent Pharma being in advanced talks to acquire KKR's stake in the company. Meanwhile, The New Shop is reportedly looking to acquire 24Seven.
View Source
Bayer acquires remaining stake in JV with Zydus Lifesciences
VCCircle
·
1y ago
Medial
German pharmaceutical company Bayer has acquired the remaining 25% stake in its joint venture (JV) with Zydus Lifesciences. The two companies formed the JV, Bayer Zydus Pharma, in 2011 for selling and marketing pharmaceutical products in India. Bayer initially held a 50% stake, which it increased to 75% in April 2018. With the recent acquisition, Bayer now has complete ownership of the JV, allowing it to leverage Zydus's marketing expertise and distribution network in India. The JV operates across various healthcare segments, including women's healthcare, metabolic disorders, and oncology.
View Source
Zydus Lifesciences ventures into medtech with acquisition of French firm
VCCircle
·
5m ago
Medial
Zydus Lifesciences Ltd has entered the medical technology sector by acquiring an 85.6% stake in the French orthopaedics firm Amplitude Surgical SA for €256.8 million. This acquisition, from PAI Partners and other shareholders, marks Zydus’ first outbound investment of 2025 and aligns with its strategy to diversify beyond its core business. The acquisition will help Zydus leverage Amplitude’s market presence and capabilities and may lead to a full acquisition valued at €300 million.
View Source
Zydus Life gets USFDA approval for Fludrocortisone Acetate tablets; shares trade flat
Money Control
·
9m ago
Medial
Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) to produce Fludrocortisone Acetate Tablets USP, 0.1 mg. The tablets are used for partial replacement therapy in certain adrenal gland disorders. This latest approval brings Zydus Lifesciences' total number of approved products to 400, with over 465 ANDA filings since 2003. The tablets will be manufactured at their facility in Moraiya, Ahmedabad. Earlier this month, the company also entered into an agreement with the Indian Council of Medical Research for clinical trials of Desidustat in Sickle Cell Disease patients.
View Source
Zydus Healthcare appoints Swati Dalal MD
Economic Times
·
1m ago
Medial
Zydus Lifesciences Ltd has appointed Swati Dalal as the Managing Director of Zydus Healthcare Ltd, effective June 16, 2025, for a five-year term. Previously the Managing Director of Abbott India Ltd, Dalal brings over three decades of experience in the healthcare industry. Her career includes leadership roles at Abbott and a strong educational background, with a pharmacy degree from PKM Kundnani College and a postgraduate degree in Management Studies from Jamnalal Bajaj Institute, Mumbai.
View Source
Gujarat group partners VC to acquire healthtech company Visit Health
VCCircle
·
11m ago
Medial
A business family from Gujarat, possibly linked to a lifesciences company, has partnered with venture capital firm Disruptors Capital to acquire healthtech company Visit Health. The privately held entity from Ahmedabad has acquired a majority stake in the company. Details of the transaction remain undisclosed.
View Source
Stocks in news: Wipro, HDFC Bank, Nazara Tech, Maruti Suzuki, Bank of Baroda
Economic Times
·
1m ago
Medial
Markets ended slightly positive amid volatility, with focus on several stocks due to various developments. Notably, Wipro saw promoter entity transactions, Vijay Kedia invested in Advait Energy, and Bank of Baroda was the highest bidder for Jet Airways' office space. Meanwhile, NTPC raised $750 million for expansion, NIIT sold its stake in NIIT-IFBI, and Zydus Lifesciences received FDA clearance. Additionally, Maruti Suzuki's merger was approved, and Sterlite Technologies signed a major BSNL contract.
View Source
'Not Exiting Sterling & Wilson', promoter says as stock crashes
Livemint
·
10m ago
Medial
- Sterling and Wilson Renewable Energy (SWRE) chairman Khurshed Daruvala clarified that his family is not exiting the company and the recent stake sale was to settle debt and fund an investment in Sterling & Wilson Data Centre. - The stake sale by Daruvala and Shapoorji Pallonji and Company Pvt. Ltd (SPCPL) caused a drop in SWRE's shares by nearly 8%. - Daruvala and his wife collectively own about 5.7% stake in SWRE, making it their largest family investment. - The stake sale was to fund an investment in Sterling & Wilson Data Centre, a company that acquired the data centre EPC business from Sterling and Wilson in a slump sale. - The sale of the data centre business by Sterling and Wilson (S&W) helped settle its debts and put an end to its debt crisis. - SWRE, which raised capital through stake sale to Reliance Industries and a qualified institutional placement, is expected to benefit from the government's focus on renewable energy and RIL's solar ambitions.
View Source
Trackers
Active Indian VC’s
OG Capital
Email
With a hands-on approach, OG Capital aims to invest in over 20 promising...
Accel Partners
Email
Early and growth-stage investments in disruptive technology companies with...
Blume
Email
Early-stage venture capital firm investing in technology startups in India. Focus on...
Access All Trackers
Startup Showcase Winners
June 2025
Buddy
Helping your parents when you are miles away
BiteStop
The Pit Stop Your Cravings Deserve
Bloomer
The next generation E-commerce platform
Enter Ongoing Startup Showcase
Top Users
Trending News on Medial
Download the medial app to read full posts, comements and news.
Go to Medial App
Not Now
Know everything that’s happening in the startup ecosystem, first.
Enable Notifications?
No, thanks
Count me in
